Less than $10/month! View ALL results for your Stocks, ETFs and Funds Screeners with Barchart Plus. FREE 30 Day Trial
or

Merck & Company (MRK)

Merck & Company (MRK)
87.98 x 6 88.04 x 1
Post-market by (Cboe BZX)
87.87 -4.44 (-4.81%) 03/25/25 [NYSE]
87.98 x 6 88.04 x 1
Post-market 88.07 +0.20 (+0.23%) 19:46 ET
Quote Overview for Tue, Mar 25th, 2025
Watch
    Add or delete the symbol from one or more Watchlists.
Day Low
87.08
Day High
92.31
Open 92.31
Previous Close 92.31 92.31
Volume 20,640,100 20,640,100
Avg Vol 17,600,000 17,600,000
Stochastic %K 24.01% 24.01%
Weighted Alpha -34.81 -34.81
5-Day Change -6.85 (-7.23%) -6.85 (-7.23%)
52-Week Range 81.04 - 134.63 81.04 - 134.63
  • 1D
  • 5D
  • 1M
  • 3M
  • 6M
  • 1Y
  • 5Y
  • MAX
Full Chart
  • OHLC Bars
  • Colored OHLC Bars
  • HLC Bars
  • Candlestick Hollow
  • Candlestick Open-to-Close
  • Candlestick Close-to-Close
  • Heikin-Ashi
  • Line Chart
  • Area Chart
  • Renko
  • Column
  • Baseline
  • Line Break
  • Range
  • Kagi
  • Point And Figure
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 233,178,368
  • Shares Outstanding, K 2,526,036
  • Annual Sales, $ 64,168 M
  • Annual Income, $ 17,117 M
  • EBIT $ 20,221 M
  • EBITDA $ 24,720 M
  • 60-Month Beta 0.35
  • Price/Sales 3.67
  • Price/Cash Flow 9.84
  • Price/Book 5.08

Options Overview Details

View History
  • Implied Volatility 33.70% ( +4.24%)
  • Historical Volatility 25.07%
  • IV Percentile 100%
  • IV Rank 100.00%
  • IV High 33.70% on 03/25/25
  • IV Low 15.09% on 05/17/24
  • Put/Call Vol Ratio 1.39
  • Today's Volume 126,641
  • Volume Avg (30-Day) 48,149
  • Put/Call OI Ratio 0.68
  • Today's Open Interest 568,220
  • Open Int (30-Day) 675,233

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 23 analysts offering recommendations.
Earnings Estimates - Current Qtr 03/31/25
See More
  • Average Estimate 2.16
  • Number of Estimates 7
  • High Estimate 2.25
  • Low Estimate 2.10
  • Prior Year 2.07
  • Growth Rate Est. (year over year) +4.35%

Price Performance

See More
Period Period Low Period High Performance
1-Month
87.08 +0.91%
on 03/25/25
Period Open: 91.43
97.37 -9.76%
on 03/07/25
-3.56 (-3.89%)
since 02/25/25
3-Month
81.04 +8.43%
on 02/18/25
Period Open: 99.45
102.97 -14.66%
on 01/07/25
-11.58 (-11.64%)
since 12/24/24
52-Week
81.04 +8.43%
on 02/18/25
Period Open: 125.31
134.63 -34.73%
on 06/25/24
-37.44 (-29.88%)
since 03/25/24

Most Recent Stories

More News
Why Pharma and Biotech Stocks Got Thrashed on Tuesday

As ever in the often quick-developing biotech and pharmaceutical sectors on Tuesday, companies posted a mix of positive and negative news. Investors clearly took the latter more to heart, as they traded...

MRK : 87.87 (-4.81%)
REGN : 634.14 (-4.06%)
AMGN : 306.86 (-2.39%)
AXSM : 120.36 (-6.82%)
Merck Enters $2B License Agreement With China-Based Hengrui Pharma For Heart Disease Drug: Retail’s Unswayed

The Chinese company will receive $200 million upfront and will be eligible to earn up to $1.77 billion in milestone payments and royalties on net sales of the drug, if approved.

MRK : 87.87 (-4.81%)
VOO : 530.65 (+0.24%)
VTI : 284.49 (+0.17%)
1 Value Stock with Solid Fundamentals and 2 to Turn Down

1 Value Stock with Solid Fundamentals and 2 to Turn Down

MRK : 87.87 (-4.81%)
EPC : 29.33 (-1.05%)
HZO : 23.32 (-1.44%)
2 Beaten-Down Stocks to Buy on the Dip

While the recent market dip has created bargains, some stocks have sufficiently lagged the market in the past year to warrant that title regardless of what's transpired in 2025. Among them are CRISPR Therapeutics...

CRSP : 40.89 (-4.06%)
MRK : 87.87 (-4.81%)
J&J's Tremfya Gets FDA Nod for 2nd IBD Condition Crohn's Disease

Johnson & Johnson JNJ announced that the FDA has granted approval to its key drug, Tremfya, for its second inflammatory bowel disease (IBD) condition — moderately to severely active Crohn’s disease...

JNJ : 161.02 (-1.39%)
MRK : 87.87 (-4.81%)
LLY : 852.35 (-1.45%)
ABBV : 201.34 (-3.74%)
Merck Loses Almost $52B in 6 Months: How to Play MRK Stock

The stock of Merck MRK has declined 19.2% in the past six months, losing almost $52 billion of its market valueThe numerous challenges plaguing the company resulted in the dilution of the stock’s market...

MRK : 87.87 (-4.81%)
SMMT : 20.24 (-2.17%)
MRNA : 33.85 (-0.94%)
Health Canada Approves KEYTRUDA® for the Treatment of Adult Patients with Primary Advanced or Recurrent Endometrial Carcinoma, in Combination with Carboplatin and Paclitaxel and then Continued as Monotherapy

/CNW/ -- Merck (NYSE: MRK), known as MSD outside of the United States and Canada, announced today that Health Canada approved KEYTRUDA® (pembrolizumab),...

MRK : 87.87 (-4.81%)
Moderna Stock Trades Near 52-Week Low: Should You Buy, Hold or Sell?

Shares of vaccine-maker Moderna MRNA closed at $34.71 on Monday, close to their 52-week low of $29.25.Moderna is facing several headwinds, including the declining COVID-19 vaccine and the soft sales performance...

MRK : 87.87 (-4.81%)
MRNA : 33.85 (-0.94%)
GSK : 38.58 (+0.03%)
PFE : 25.55 (-2.26%)
GILD Stock Trading Close to Its 52-Week High: Should You Buy or Sell?

Gilead Sciences, Inc. GILD hit a 52-week high of $119.96 on March 10. The stock is currently trading at $111.44.Shares have also gained 5.5% in the past month compared with the industry’s growth of 1.2%....

MRK : 87.87 (-4.81%)
GILD : 107.89 (+1.08%)
GSK : 38.58 (+0.03%)
Should You Buy the 3 Highest-Paying Dividend Stocks in the Dow Jones?

The Dow Jones Industrial Average (DJINDICES: ^DJI) is one of the most-watched stock indexes on Wall Street. Its list of components is rather small; that small list, however, means these are cherry-picked...

TMUS : 258.75 (-0.08%)
CVX : 165.94 (+0.56%)
VZ : 43.49 (-0.16%)
T : 27.31 (+1.30%)
$SPX : 5,776.65 (+0.16%)
MRK : 87.87 (-4.81%)
$DOWI : 42,587.50 (+0.01%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Sell with a Strengthening short term outlook on maintaining the current direction.

Long term indicators fully support a continuation of the trend.

See More Share

Business Summary

Merck & Co. boasts more than six blockbuster drugs in its portfolio with PD-L1 inhibitor, Keytruda, approved for several types of cancer. Keytruda has played an instrumental role in driving Merck's steady revenue growth in the past few years. Well-known products in Merck's portfolio include Keytruda,...

See More

Key Turning Points

3rd Resistance Point 96.32
2nd Resistance Point 94.32
1st Resistance Point 91.09
Last Price 87.87
1st Support Level 85.86
2nd Support Level 83.86
3rd Support Level 80.63

See More

52-Week High 134.63
Fibonacci 61.8% 114.16
Fibonacci 50% 107.84
Fibonacci 38.2% 101.51
Last Price 87.87
52-Week Low 81.04

See More

Want to use this as
your default charts setting?
Save this setup as a Chart Templates
Switch the Market flag
for targeted data from your country of choice.
Open the menu and switch the
Market flag for targeted data from your country of choice.
Want Streaming Chart Updates?
Switch your Site Preferences
to use Interactive Charts
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.
Use your up/down arrows to move through the symbols.
Free Barchart Webinar
Precision Trading with Bollinger Bands: Identifying Breakouts & Reversals